(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved XELJANZ® (tofacitinib citrate) for the treatment of adults with rheumatoid arthritis (RA) who have had an inadequate response to existing therapies. XELJANZ may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying antirheumatic drug (DMARD
You are here
Press Release Archive
SAN FRANCISCO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from the REMINDER trial showing statistically significant risk reductions in the primary composite efficacy endpoint. The composite endpoint was defined as the time to first event of cardiovascular (CV) mortality, re-hospitalization or extended initial hospital stay due to diagnosis of heart failure (HF), sustained ventricular tachycardia or fibrillation, ejection fraction (EF) ≤40% after 1 month,
BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13Â® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])in adults infected with human immunodeficiency virus (HIV). The results were presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, Ga. These data support planned regulatory
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced top-line results for a Phase 3 study that showed Lyrica® (pregabalin) Capsules CV were as effective as levetiracetam as an adjunctive therapy in adult epilepsy patients experiencing refractory partial onset seizures. The top-line results indicate that the study met its primary endpoint by demonstrating that a comparable proportion of patients on Lyrica achieved at least a 50 percent reduction in
(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, President and General Manager, Specialty Care and Oncology, at the Citi 2013 Global Healthcare Conference on Tuesday, February 26, 2013 at 4:35 p.m. Eastern Standard Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the â€œCiti 2013 Global Healthcare Conferenceâ€ link in the Investor
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its former animal health business unit, now a standalone company named ZoetisTM, began trading on the New York Stock Exchange under the ticker symbol "ZTS." "This is a proud moment for all Zoetis and Pfizer employees," said Ian Read, chairman and chief executive officer of Pfizer. "With the Zoetis initial public offering, we are creating the largest standalone company fully devoted to animal
(BUSINESS WIRE)--Pfizer Inc. said today that the United States District Court for the District of Delaware ruled that Pfizerâ€™s patent covering a method for using sirolimus, the active ingredient in RAPAMUNEÂ®, for the inhibition of organ transplant rejection is valid and infringed. The company brought a patent infringement action in April 2010 against the generic company Watson Laboratories, Incâ€”Florida (now known as Actavis) and three other Watson entities after
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the companyâ€™s pneumococcal conjugate vaccine, Prevnar 13Â®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes
(BUSINESS WIRE)--ChapStick® is giving healthier, happier lips another reason to smile next month. The ChapStick® brand is collaborating with the recently re-launched social entertainment destination Myspace to host a national live stream concert event featuring Emeli Sand© and other rising stars on Monday, February 11, 2013, at the Key Club in Los Angeles. The event is part of ChapStick® Sessions, a national initiative that celebrates what healthier, happier
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that a Phase 4 study assessing the efficacy and safety of Toviaz® (fesoterodine fumarate) 8 mg once daily in patients with overactive bladder (OAB) compared to Toviaz 4 mg once daily or placebo met its primary endpoint. The primary endpoint was change in mean number of urge urinary incontinence episodes per 24 hours from baseline to week 12. Toviaz 8 mg reduced urge urinary incontinence in patients with
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that a Phase 4 study evaluating the efficacy of PRISTIQÂ® (desvenlafaxine) Extended Release Tablets met its primary endpoint. The study supports the efficacy of 50 mg/day and 100 mg/day doses of PRISTIQ compared with placebo over eight weeks of treatment in adult patients with major depressive disorder (MDD) as measured by the 17-item Hamilton Rating Scale for Depression (HAM-D17) total score.1
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that a post-marketing study assessing the efficacy and safety of varenicline (CHANTIX®/CHAMPIX®) in a population of smokers who had made a previous attempt to quit smoking with CHANTIX, and either did not succeed in quitting or relapsed after treatment, met its primary endpoint. CHANTIX significantly increased continuous abstinence rates compared to placebo at weeks nine to 12, the last four weeks
(BUSINESS WIRE)--Pfizer Inc. is proud to celebrate the 10th anniversary of its Global Health Fellows Program (GHF) as part of its corporate social investment strategy that focuses on leveraging the full range of the company's resources -- people, medicines, expertise and funding -- to broaden access to medicines and strengthen health care delivery for underserved people around the world. GHF is Pfizer's signature corporate volunteer program that pairs
(BUSINESS WIRE)--Pfizer Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the conditional marketing authorization of bosutinib in the European Union (EU) for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) previously treated
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that Quillivant XR™ (methylphenidate hydrochloride) CII for extended-release oral suspension is now available in the U.S. for the treatment of attention deficit hyperactivity disorder (ADHD). Quillivant XR is the first once-daily, extended-release liquid methylphenidate for ADHD and is now available by prescription. "In order to effectively treat patients with chronic conditions such as
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved expanding the use of the company's pneumococcal conjugate vaccine, Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), to older children and adolescents aged 6 to 17 years for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by vaccine-type Streptococcus pneumoniae. Children in this
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Rebif® Rebidose® (interferon beta-1a), a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS). (Logo: http://photos.prnewswire.com/prnh/20130103/SF36310LOGO) (Logo: http://photos.prnewswire.com/prnh/20121220/SF32295LOGO-b) (Logo: http://photos
ELIQUIS Demonstrated Superior Risk Reductions Versus Warfarin in Three Key Outcomes—Stroke and Systemic Embolism, Major Bleeding and All-Cause Mortality—for Patients with Nonvalvular Atrial Fibrillation
Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.